R&D BMS looks for cancer combos with Cormorant buy Bristol searching for new immuno-oncology combinations.
News Novartis buys into bispecific antibodies with Xencor deal Agreement could add to Novartis' immuno-oncology pipeline.
Cancer Novartis' Afinitor gets new EU cancer use Novartis’ Afinitor has been approved in a new cancer indication in Europe – but faces potential competition from newer drugs.
Cancer FDA accepts Keytruda head and neck cancer filing Merck's PD-1 inhibitor Keytruda (pembrolizumab) has been accepted for priority review by the FDA in another new setting, head and neck cancer.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
